subject: The Rapid Development Of Chinese Bio-pharmaceutical Industry - Tile Texture - China Corrugation [print this page] In recent years, the rapid development of bio-pharmaceutical industry last year, output value of 8,666 billion yuan (RMB), an increase of 25.23%. Among them, bio-pharmaceuticals grew 30.65 percent, an increase of 31.43% of medical equipment.
And industrial and high-tech industry development, the Chinese bio-pharmaceutical industry is less affected by the global financial crisis, anti-risk ability, continue to maintain rapid growth, largely due to the rigidity of the demand characteristics of pharmaceutical products.
As a biological important areas of industrial development, China will vigorously develop the bio-pharmaceutical industry. Over the next 10 years, a group of gene therapy program, the drug will enter the application stage, will form a chemical medicine, Chinese medicine, bio-medicine the three pillars of a new pattern of drugs.
In recent years, cancer, heart disease, high blood pressure, diabetes, neurological diseases and other major diseases, 200 biological drugs to obtain the certificate, developing nearly 200 species of bio-medicine, bio-medicine into the nearly 400 clinical trials, bio-pharmaceuticals as new industries.
At present, China Pharmaceutical Biology class a total of 124 listed companies realized main business income of 91.704 billion yuan, an increase of 15%; to achieve net profit of 4.4 billion, an increase of 43%; the average return on equity from 1.13% a year earlier to 4.77%. In addition, 124 companies of the investment income from the sum of 445 million yuan a year earlier jumped to 1.542 billion yuan, an increase of up to 246%.
Over the past 10 years, China has intensified efforts to support the biomedical innovation system and support the important biological medical products industry based in the biomedical related fields have established a number of national engineering research centers, has over 27 species of biotech drugs to achieve self-innovation of industrialization, providing the market with more than 300 kinds of bio-medical products, industrial-scale sustained rapid growth, initially forming a bio-pharmaceutical innovation and development of a sound foundation.
After 20 years of rapid development, China's pharmaceutical industry, production capacity is highest in the world, including pharmaceutical processing capacity ranking first in the world production of chemical raw materials ranked second worldwide. At present, China's pharmaceutical industry tablet 100 million annual production capacity has reached 6,200, 1,194, 100 million capsules, water-pin 56.3 billion, 4.4 billion infusion bottles (bags), powder for injection 17.5 billion. Chinese medicine production of chemical raw materials and intermediates up to more than 1,300 varieties, the total annual output of more than 800,000 tons, of which nearly 50% of exports, accounting for 25% of the world's raw material drug trade around.
Statistics show that in 2000 the world's 50 U.S. dollars per capita consumption of drugs, the United States 300 U.S. dollars per capita consumption of drugs, the Chinese less than 10 U.S. dollars. But authorities said that the Chinese pharmaceutical market has great potential in the future will be 5,6 years, 15% to 20% pace. According to an estimate, China's pharmaceutical market in 2000 reached 15 billion U.S. dollars in 2020 will reach 1,200 billion U.S. dollars, which surpassed the U.S. as the world's largest market.
Stimulated by the favorable factors, foreign pharmaceutical companies scrambling to increase its investment in China. According to incomplete statistics, multinational pharmaceutical companies to establish R & D centers in China so far the total investment amounts to more than 500 million U.S. dollars.
The first multinational pharmaceutical companies to enter China, is the production and sales, and now are gradually turned into R & D, production and sales through-train. Transnational pharmaceutical companies to reduce development costs to establish R & D centers in China, but also reduce the drug costs of listing products in the Chinese market competitiveness will increase markedly.
In the global pharmaceutical companies in the top 5 of the AstraZeneca is investing 100 million U.S. dollars in the Wuxi factory established, as early as April 2001 has been officially put into operation, which is the company's largest investment project in Asia, but also cross-Pharmaceutical investment in China, one of the largest projects. One of the world's 20 largest pharmaceutical company, Boehringer Ingelheim International Group, most recently in the Pudong Zhangjiang Hi-Tech Park to build a new plant. This cost of 4,100 million plant is the group's second-largest plant in Asia. Currently residing in first place in the global pharmaceutical industry, GSK's investment in China is the biggest investment in the Asia-Pacific region, but also the Group over the past five years, the biggest investment made by the pharmaceutical field, including last year by the end of October officially put into operation in Tianjin The registered capital of 9,200 million U.S. dollars invested in factories and amounted to 136 million U.S. dollars in Suzhou plant.
Pudong Zhangjiang Hi-Tech Park has attracted in recent years, Roche, SmithKline Beecham, Boehringer Ingelheim, Medtronic, Nycomed, unicorn represented by dozens of multinational pharmaceutical companies. With the foreign seas, Qiao Yuan, Pioneer Pharmaceutical Co., represented by the large state-owned enterprises, to Green Valley Group, represented by private enterprises in order to minimally invasive medical devices, represented by foreign students have entered the Zhangjiang enterprises with foreign counterparts on the same stage Competitive. The world's top 20 multinational pharmaceutical companies have set up factories in China, a joint venture, and some also have their own wholly-owned enterprises. In the current China's largest 500 foreign-funded enterprises, the pharmaceutical companies accounted for 14 companies, of which there are 13 foreign owned. Xian-Janssen foreign holding 52%, Tianjin, China-US GSK foreign holding 55%.
